Amgen, Samsung Test Blood Drug Patent In 'Biosimilars' Race
Drugmakers Amgen Inc. and Samsung Bioepis have filed separate claims seeking to invalidate a patent vital for treating the ultra-rare blood disorder drug Soliris, as the two companies vie to bring...To view the full article, register now.
Already a subscriber? Click here to view full article